A protein recruited to activated GPCRs that uncouples them from G protein signalling and drives their internalisation. It is the normal off-switch.

Does biased agonism explain tirzepatide's advantage?

Partly, perhaps. It is a second contribution alongside GIP receptor agonism, and it is not yet established how much of the clinical difference it accounts for.

Is more bias always better?

Not established. Bias is assay-dependent and the link between measured bias and clinical outcome is not straightforward.

GLP-1 & Incretin Science

Biased Agonism at the GLP-1 Receptor

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Biased agonism means a ligand preferentially activates some downstream pathways over others at the same receptor. At the GLP-1 receptor, favouring cAMP signalling while limiting β-arrestin recruitment reduces receptor internalisation, prolonging signalling. Tirzepatide shows this bias; native GLP-1 does not.

Key facts

Definition: Ligand-specific preference among downstream pathways
Pathway favoured: cAMP / G protein
Pathway limited: β-arrestin recruitment
Consequence: Reduced receptor internalisation
Result: Prolonged signalling from the cell surface
Example: Tirzepatide at GLP-1R
Key reference: PMID 33268378

What a receptor does after it is activated

Activation is not the end of the story. A G-protein-coupled receptor engages G proteins, generating second messengers such as cAMP, and separately recruits β-arrestin. β-arrestin does two things: it uncouples the receptor from G protein signalling, and it drives internalisation, pulling the receptor off the cell surface. That is the normal mechanism by which a signal is switched off.

Where bias comes in

Different ligands binding the same receptor can favour these arms to different degrees. A ligand producing strong cAMP signalling with weak β-arrestin recruitment activates the receptor without efficiently triggering its own shutdown. The receptor stays at the plasma membrane and keeps signalling. This ligand-specific preference is what biased agonism means, and it is a property of the ligand, not of the receptor.

Why this matters for incretin drugs

Reported work shows that biased signalling toward cAMP with limited β-arrestin recruitment prevents internalisation at both GLP-1R and GIPR, and that GLP-1 analogues with selectively reduced β-arrestin-2 recruitment produce less endocytosis and more sustained insulin secretion. At GLP-1R, tirzepatide favours cAMP accumulation over β-arrestin recruitment and is less effective at inducing internalisation than the native ligand — retaining receptor at the surface and generating greater efficacy.

A better explanation than 'it adds GIP'

Tirzepatide's advantage over semaglutide is usually attributed entirely to GIP receptor agonism. Biased signalling at the GLP-1 receptor is a second, independent contribution, and it may account for part of the gap. This matters because it makes the GIP paradox less puzzling: if some of tirzepatide's edge comes from how it signals rather than from which receptors it hits, then a GIPR antagonist producing comparable results is less contradictory than it first appears.

The design implication

If bias is a tunable property, it becomes a design target alongside receptor selectivity and half-life. Work has reported GLP-1 analogues optimised specifically for cAMP-biased signalling, and dual GLP-1R/GIPR biased agonism has been reported to yield greater efficacy than bias at either receptor alone. This is a different axis of optimisation from adding receptors, and the two can be pursued together.

What remains uncertain

Much of this work is preclinical or in cell systems, and the relationship between measured bias in an assay and clinical outcome in a person is not simple. Bias is also assay-dependent — the same ligand can appear differently biased depending on what is measured and in which cell type. Treat it as an active and promising area rather than a settled explanation.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What is β-arrestin?: A protein recruited to activated GPCRs that uncouples them from G protein signalling and drives their internalisation. It is the normal off-switch.
Does biased agonism explain tirzepatide's advantage?: Partly, perhaps. It is a second contribution alongside GIP receptor agonism, and it is not yet established how much of the clinical difference it accounts for.
Is more bias always better?: Not established. Bias is assay-dependent and the link between measured bias and clinical outcome is not straightforward.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum